Description
Letromara Coated Tablets 2.5 mg. №30
Ingredients:
Each coated tablet contains 2.5 mg of Letrozole.
Mechanism of Action:
Letrozole, the active ingredient in Letromara, inhibits aromatase, an enzyme responsible for estrogen production. By reducing estrogen levels, Letrozole effectively slows or halts the growth of hormone-sensitive tumors.
Pharmacological Properties:
Letrozole belongs to the class of medications known as aromatase inhibitors. It works by blocking the conversion of androgens to estrogens, thereby lowering circulating estrogen levels in the body.
Indications for Use:
Letromara is specifically indicated for the treatment of hormone receptor-positive breast cancer in postmenopausal women. It is prescribed to reduce the risk of cancer recurrence in this patient population.
Contraindications:
Avoid using Letromara if you are pregnant, breastfeeding, or have a known allergy to Letrozole. It is crucial to discuss any existing medical conditions or medications with your healthcare provider before starting Letromara treatment.
Side Effects:
Common side effects of Letromara may include hot flashes, fatigue, joint pain, and nausea. In rare cases, more severe side effects such as bone fractures or cardiovascular events may occur. Contact your doctor immediately if you experience any unusual symptoms while taking Letromara.
Usage Instructions:
The recommended dosage of Letromara is one 2.5 mg tablet to be taken orally once daily. It can be consumed with or without food, preferably with a full glass of water. Adhering to the prescribed dosage and schedule is essential for optimal treatment outcomes.
Benefits Compared to Analogues:
Studies have demonstrated the superior efficacy of Letrozole, the active ingredient in Letromara, compared to tamoxifen in reducing the risk of cancer recurrence in postmenopausal women with hormone receptor-positive breast cancer. Letromara may offer improved outcomes and a more favorable side effect profile compared to alternative hormonal therapies.
Suitable Patient Groups:
Letromara is intended for use in postmenopausal women diagnosed with hormone receptor-positive breast cancer. It is not recommended for individuals who are premenopausal or have not been diagnosed with this specific type of breast cancer. Consult with your healthcare provider to determine the suitability of Letromara for your condition.
Storage and Shelf Life:
Store Letromara tablets at room temperature away from moisture and heat. Ensure that the medication is kept in its original packaging to protect it from light exposure. Check the expiration date on the packaging and do not use Letromara beyond the stated shelf life.
Packaging Description:
Letromara is available in blister packs containing 30 coated tablets, with each tablet clearly labeled with the dosage strength of 2.5 mg. The packaging is designed to maintain the integrity and stability of the medication throughout its shelf life.
